Oliva, A.; Echezarreta, M.; Santana-Mayor, Á.; Conde-Díaz, A.; Goncalves, J.; Chow, S.-C.; Llabrés, M.
Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain. Pharmaceutics 2024, 16, 1520.
https://doi.org/10.3390/pharmaceutics16121520
AMA Style
Oliva A, Echezarreta M, Santana-Mayor Á, Conde-Díaz A, Goncalves J, Chow S-C, Llabrés M.
Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain. Pharmaceutics. 2024; 16(12):1520.
https://doi.org/10.3390/pharmaceutics16121520
Chicago/Turabian Style
Oliva, Alexis, Magdalena Echezarreta, Álvaro Santana-Mayor, Adrían Conde-Díaz, Joao Goncalves, Shein-Chung Chow, and Matías Llabrés.
2024. "Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain" Pharmaceutics 16, no. 12: 1520.
https://doi.org/10.3390/pharmaceutics16121520
APA Style
Oliva, A., Echezarreta, M., Santana-Mayor, Á., Conde-Díaz, A., Goncalves, J., Chow, S.-C., & Llabrés, M.
(2024). Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain. Pharmaceutics, 16(12), 1520.
https://doi.org/10.3390/pharmaceutics16121520